• Required warfarin doses for mechanical heart valves vary greatly.
Essentials
• Required warfarin doses for mechanical heart valves vary greatly.
• A two-stage extreme phenotype design was used to identify novel warfarin dose associated mutation.
• We identified a group of variants significantly associated with extreme warfarin dose.
• Four novel identified mutations account for 2.2% of warfarin dose discrepancies.
Summary. Background:
The variation among patients in warfarin response complicates the management of warfarin therapy, and an improper therapeutic dose usually results in serious adverse events. Objective: To use a twostage extreme phenotype strategy in order to discover novel warfarin dose-associated mutations in heart valve replacement patients. Patients/method: A total of 1617 stable-dose patients were enrolled and divided randomly into two cohorts. Stage I patients were genotyped into three groups on the basis of VKORC1-1639G>A and CYP2C9*3 polymorphisms; only patients with the therapeutic dose at the upper or lower 5% of each genotype group were selected as extreme-dose patients for resequencing of the targeted regions. Evaluation of the accuracy of the sequence data and the potential value of the stage I-identified significant mutations were conducted in a validation cohort of 420 subjects. Results: A group of mutations were found to be significantly associated with the extreme warfarin dose. The validation work finally identified four novel mutations, i.e. DNMT3A rs2304429 (24.74%), CYP1A1 rs3826041 (47.35%), STX1B rs72800847 (7.01%), and NQO1 rs10517 (36.11%), which independently and significantly contributed to the overall variability in the warfarin dose. After addition of these four mutations, the estimated regression equation was able to account for 56.2% (R
Introduction
Clinical treatment of warfarin is problematic, because of the narrow therapeutic index and serious adverse effects. It is critical to predict an appropriate therapeutic dose for patients before treatment, because overdosing usually lead to hemorrhagic complications, and underdosing leaves patients at risk of clot formation [1, 2] . Factors such as clinical characteristics, demographic variables and hereditary variations have all been shown to influence warfarin dose [3] . Much effort has been devoted to determining whether the use of pharmacogenetic algorithms to predict therapeutic warfarin dose is superior to the standard dose strategy using time in therapeutic range and rate of adverse events as evaluation indicators [4, 5] . The most equivocal conclusions were from two prospective, randomized controlled trials published in 2013 [6, 7] . One possible reason, we suppose, for these contradictory results is that the pharmacogenetic algorithms used in the previous prospective studies only included VKORC1-1639G>A, CYP2C9*2 and CYP2C9*3 variants, and these mutations can predict an appropriate dose for only a proportion of patients. Importantly, patients with complex warfarin indications were enrolled in these studies, and this may also influence the performance of pharmacogenetic algorithms [8] . Data from our previous study showed that pharmacogenetics-based algorithms developed from only heart valve replacement (HVR) patients performed better than most of the published algorithms, which were established by the use of patients with complex indications [9] . Importantly, warfarin pharmacogenetic algorithms, which were established by the use of subjects with various warfarin indications, did not have desirable prediction accuracies for HVR patients [8] . Thus, we considered that further studies should highlight the need for populationspecific data. In China, rheumatic heart disease has a significantly higher prevalence than in Europeans and Caucasians [10, 11] . Also, patients after HVR surgery usually need warfarin anticoagulation treatment for a long time or even lifelong. Identifying additional genetic factors that affect warfarin dose in Chinese HVR patients is critical for extending the benefits of genotype guidance.
The main objective of this study was to explore novel warfarin dose-associated mutations in Chinese HVR patients by use of a two-stage extreme phenotype strategy. This study design was based on the premise that the functional or significant mutations, which usually occur at a very low frequency, were more frequently present in patients with extreme phenotypes [12, 13] . Targeted resequencing of candidate regions in patients with an extreme quantitative phenotype is a novel and cost-effective method to gain information on the contribution of other mutations to warfarin responses, especially the rare variations [14] [15] [16] .
Patients and methods

Study approval
This study was conducted in compliance with the stipulations of the Declaration of Helsinki. The study protocol was approved by the Ethics Committee of the Institute of Clinical Pharmacology at Central South University (CTXY-110005), and the trial was registered: ChiC-TRONC-11001532. Written informed consent was received from participants prior to enrollment. Participants were identified by numbers, and not by names.
Data collection
All of the data were collected from the primary patient population, by a review of inpatient and outpatient medical records. These clinical factors were mainly obtained from the electriconic medical records, including demographic variables (age, sex, height, weight, and smoking and drinking habits), clinical characteristics (indications for warfarin medication, including mechanical valve prosthesis or bioprosthetic heart valves, and aortic valve or mitral valve or tricuspid valve replacement), and coexistent disease (hypertension, coronary heart disease, diabetes mellitus, stroke, atrial fibrillation etc.).
All of the patients returned regularly for adjustment of the therapeutic dose on the basis of the International Normalized Ratio (INR) results. We recorded the INR, warfarin dosage and the drug combination situation (drugs that can increase or decrease the INR) at each follow-up visit. The hereditary variations were detected after patients had reached the stable dose. Warfarin stable dosage (WSD) was determined for patients as the last stable dosing interval achieved 1 week ago or later that was associated with two or more continuous therapeutic INRs measured 1 week or more apart with a dosing change of < 10%.
Inclusion and exclusion criteria
Inclusion criteria Previously warfarin-naive HVR patients who needed long-term or lifelong warfarin for anticoagulant therapy and had a target INR of 2.0-3.0 were enrolled in this study. Patients also had to be > 18 years of age and be able to attend the schedule visits. All included patients had already achieved a stable dose and had available DNA samples.
Exclusion criteria
The other clinical indications for the use of warfarin were severe liver or kidney function dysfunction, malignant tumor, severe heart failure or cardiomyopathy, pregnancy, or lactation.
Genotyping method
Polymorphisms of VKORC1-1639G>A and CYP2C9*3 in the whole study were genotyped by pyrosequencing. The targeted region resequencing was completed with a nextgeneration sequencing platform. The experimental procedures for the next-generation sequencing are described here. First, the qualified genomic DNAs were randomly fragmented into DNA fragments with a base pair peak at 200-300 bp, and adapters were then ligated to both ends of the resulting fragments. Extracted DNAs were amplified by ligation-mediated PCR (LM-PCR) after being purified, and were hybridized to the NimbleGen human exome array for enrichment; the non-hybridized fragments were then washed out. Both non-captured and captured LM-PCR products were subjected to quantitative PCR to estimate the magnitude of enrichment. Each captured library was then loaded on the Hiseq 2000 platform, and high-throughput sequencing was performed for each captured library to ensure that each sample met the desired average fold coverage, after which image analysis and base calling were performed.
Genotyping of all validated single-nucleotide polymorphisms (SNPs) was performed by matrix-assisted laser desorption/ionization time-of-flight mass spectrometry with a MassARRAY Analyzer 4 platform (Sequenom, San Diego, CA, USA). Primers were designed with the accompanying software, SPECTRODESIGNER; multiplexing and homogeneous mass-extension processes were used to produce the primer extension products.
Study design
The total study design contained two stages, as shown in Fig. 1 Stage I: extreme-dose-associated SNP discovery by resequencing the targeted regions of patients with extreme warfarin doses The sample size for stage I was based on the following hypothesis. An independent case-control study was conducted, and the type I error (a) was 0.05, the statistical power was 0.8, the probability of exposure in cases (p0) was 0.15, the ratio of control to case patients (m) was 1, and the odds ratio (OR) of exposure (w) was 3.5. On the basis of these parameters, the calculated sample size was 56.
We used next-generation sequencing method to resequence the exons, exon-intron boundaries and gene regulatory regions of 43 target genes or regions that were potentially associated with warfarin dosage. These warfarin dose-associated genes or areas were selected on the basis of the PharmaGKB website, the results of genome-wide association studies, or the results of other published studies [17] [18] [19] [20] [21] [22] linkage disequilibrium (LD) (r 2 > 0.9). The further validated work was based on a moderate sample size (N = 420). During the validation study, we first evaluated the accuracy of the genotype calls of stage I by randomly regenotyping 22 SNPs that were all present in the dbSNP database. Second, we further verified the statistically significant warfarin response-related SNPs in a larger sample size. Genotyping of stage II was based on the MassAR-RAY platform.
Statistics
All analyses were performed with R version 2.5.1 (R Foundation for Statistical Computing, Vienna, Austria), SPSS STATISTICS version 19.0 (SPSS, Chicago, IL, USA), and PLINK 1.9 (http://pngu.mgh.harvard.edu/purcell/plink/ ). Means and standard deviations were calculated for continuous variables, and frequencies and percentages were calculated for categorical variables. The t-test (for continuous variables) and v 2 test (for categorical variables) were used to analyze the differences in characteristics between high-dose and low-dose patients.
Extreme warfarin dose was treated as a binary variable, with high-dose patients as cases and low-dose patients as controls. P-values for stage I were considered to be significant with a cutoff of 0.05. Both common variants and less common variants (LCVs) (minor allele frequency [MAF] of < 5%) were focused on in stage I. For common variants, a binary case-control association test was performed by use of chi-squared testing (À logist), and with high WSD patients as cases and low WSD patients as controls. SNPs were first filtered for Hardy-Weinberg equilibrium (HWE) in the controls (À hwe 0.001). A genotyping rate of > 0.9 (À geno 0.9), a MAF of > 5% (À maf 0.05) and a single-variant test under an additive genetic model were used to test the association.
For LCVs, a model-free method (the Burden test) was used [17] . This strategy could increase the power for detecting an association by using variants of low allele frequencies with moderate relative risk and cohort sizes. With this statistical method, we first identified SNPs that were significantly associated with phenotypes (P < 0.05), and further divided these SNPs into different loci based on the location. A mutation located in one gene or not more than 5 kb away was regarded as a single polymorphic mutation. Patients with one or more SNPs were defined as mutant carriers, and others were defined as wild-type carriers [23, 24] .
LD between SNPs was visualized with HAPLOVIEW. Pairwise LD was quantified by use of the standard r 2 measure. Univariate and multivariable analyses of theimpact of mutations on warfarin dose were performed using linear regression analyses. The coefficient of determination, R 2 , was used to measure the proportion of explained variance. The final pharmacogenetics models were based on verified findings, and only significant variables (P < 0.05) were allowed in the final model. The performance of the final model was evaluated with cross-validation to achieve unbiased estimates (by 10-fold cross-validation).
Results
Characteristics of patients enrolled in this study
Between 2012 and March 2014, 2924 warfarin-naive patients were enrolled in this study. During the whole observation period, 2104 patients reached a stable dose. In total, 1617 patients (3.01 AE 1.03 mg per day) with intact clinical data and available DNA samples were included in further analyses. These patients were firstly divided into two groups: 1197 (3.03 AE 1.04 mg per day) were enrolled in stage I, and 420 (2.95 AE 1.02 mg per day) were enrolled in stage II. The basic characteristics of the patients in these two cohorts are shown in Table 1 .
Stage I patients (N = 1197) were secondly divided into three groups: AA&*1*1 genotype group (N = 884); AA&*1*3 or AA&*3*3 genotype group (N = 93); and GA&*1*1 or GG&*1*1 genotype group (N = 220). A total of 122 extreme-dose patients were finally selected, and the baseline clinical characteristics were comparable between the upper and lower groups, except for age, as shown in Table S1A -C. There were 38 pairs of AA&*1*1 genotype patients with extremely high (4.65 AE 0.56 mg per day) or low (1.46 AE 0.17 mg per day) warfarin dose. Fourteen extremely high-dose (6.04 AE 0.50 mg per day) and 13 extremely low-dose (2.23 AE 0.42 mg per day) patients were eventually enrolled in the GA&*1*1 or GG&*1*1 genotype group, and nine extremely high-dose (3.44 AE 0.77 mg per day) and 10 extremely low-dose (0.97 AE 0.27 mg per day) patients were enrolled in the AA&*1*3 or AA&*3*3 genotype group.
Identification, filtering and characterization of identified variants
We finally resequenced 144 targeted regions that covered the exons, splice sites and regulatory areas (2 kb of the 3 0 -untranslated region [UTR] and 2 kb of the 5 0 -UTR) of 43 candidate genes or regions, givimg 582.8 kb in total. Each sample was sequenced at a median coverage of greater than 9 100 across the targeted intervals, and the average coverage of targeted regions was 93%. A total of 3398 raw SNPs were polymorphic in the 122 sequenced extreme samples after mapping of the high-quality reads by filtering and the reference genome sequences.
We implemented a number of quality filters to establish a reliable set of SNPs in this study. First, we excluded SNPs with a MAF of 0. Second, we removed SNPs with a P-value of < 0.001 after HWE testing. Third, we removed SNPs for which < 90% of the samples had valid genotype calls. As a result, 92 SNPs failed frequency testing (MAF = 0), 87 markers were excluded on the basis of HWE testing, and 342 SNPs failed missingness testing.
After the filtering processes, 2941 high-confidence SNPs were achieved in the sequenced cohort for sequencebased association studies, and we further annotated the locations and potential functional effects of these mutations. Of the filtered SNPs, 1564 (43.18%) of 2941 are present in the dbSNP databases. Of the 1781 newly identified SNPs, 1197 were found only once, and with a MAF of < 1%. The overall filtering processes and SNP location distributions of these mutations are shown in Fig. 2 .
Quality assessment of the sequence-based genotype by comparison with an alternative genotyping method
To evaluate the accuracy of the sequence data, we independently genotyped 17 randomly selected SNPs, which were all present in the dbSNP database, from 95 samples of the 122 extreme individuals. After comparing the sequence-derived genotypes of each subject with the corresponding MassARRAY-generated genotypes, we found that 1.99% (34 of 1710 comparisons) of the genotypes were in disagreement between these two methods, as shown in Table S2 . The P-value of each SNP passed HWE statistical testing (> 0.01), indicating that the genotyping method of stage I was correct.
Association of variations with extreme warfarin dose
Single-variant test There were 39 SNPs that were significantly associated with extreme warfarin dose after comparison of the allele frequencies of mutations between the upper-dose group and lower-dose group, as shown in Table S3 (chi-square P < 0.05). After noting the locations of these SNPs, we found that most of the identified mutations were located in CYP4F2, EPHX1, NQO1, and STX1B. LD analysis was carried out, haplotype analysis showed that the gene loci consisting of these positive SNPs were also significantly associated with extreme warfarin dose, as shown in Table 2 . We also conducted the association analysis in three genotype groups as shown in Fig. S2A-C . The results showed that the significant SNPs in different genotypes were different from each other.
Collapse statistical method Seven LCVs were selected with a model-free method, as shown in Table S4 ; all of them were divided into two gene loci. These locus variants were significantly associated with extreme warfarin dose, as shown in Table 3 . The G1 interval contained two SNPs (SNP96833210 and SNP968334982) located in the upstream of CYP2C8; these had a higher frequency in the low-dose group than in the high-dose group (19.67% versus 3.39%; OR 0.143; 95% confidence interval [CI] 0.031-0.67; P = 0.009). The G2 intervals contained five SNPs, three (rs61239537, rs12920772, and rs72800847) of which were located in the intron of STX1B, and two (rs12447930 and rs4889609) of which were situated upstream of STX1B. The G2 intervals had a high frequency in the high-dose group (OR 4.03; 95% CI 1.23-13.19; P = 0.019). Interestingly, after comparison of the mutation frequencies of the G2 intervals in different VKORC1 -1639G>A & CYP2C9*3 genotype groups, G2 polymorphisms were mainly present in the GA&*1*1 genotype group (MAF = 94.1%; Table S5 ), and were associated with higher warfarin dose, as shown in Table S5 (P = 0.006; OR 13.5; 95% CI 2.01-90.69).
Validation of the observed significant SNPs in stage I
A total of 48 SNPs were validated in stage II, as shown in Table S6 . The primers for these SNPs validated by MASSarray were shown in Table S7 . Five of the validated mutations (rs200687488, rs200681363, SNP967 39768, SNP96833498, and SNP29170636) did not show polymorphism genotypes in the validation cohort. The association between polymorphisms and WSD was firstly calculated by univariate analysis, and results showed that 10 mutations were significantly associated with warfarin dose, as shown in Table 4 . Interestingly, the most significant polymorphisms, i.e. rs72800847, rs4889609, and rs9934438, were in LD (r 2 = 0.609). To assess the effective genetic factors for warfarin maintenance dose, data were analyzed with respect to body surface area, age, sex, smoking and drinking habits, co-medications, coexistent disease, and genetic polymorphisms of VKORC1 and CYP2C9. A multiple regression model was used to evaluate the adjusted effects of SNPs with P-values of < 0.15 on univariate analysis. The results of multivariate analysis showed that DNMT3A (rs2304429), CYP1A1 (rs3826041), STX1B (rs72800847 or rs4889609) and NQO1 (rs10517) made independent and significant contributions to the overall variability in warfarin dose. The multivariate linear regression equation of warfarin maintenance dose was as follows: dose = 0.38 + 0.3femal À 0.01age + 0.72MHVR À 0.35 hypertension + 0.61DM2 À 0.48Amiodarone + 1.14BSA + 0.38rs2304429AA + 0.69CYP2C9*1*1 + 0.22rs3826041-CC À 0.96rs72800847GA À 0.76 rs72800847AA + 1.38 VKORC1 À 1639GA + 1.78VKORC1 À 1639AA + 0.26-rs10517TT + 0.29rs2108622CT. The estimated regression equation was able to account for 56.2% (R 2 Adj = 0.562) of the overall interpatient variation in WSD, and this new prediction algorithm had a predictive accuracy of 62.4%. These four novel added mutations can explain 2.2% of warfarin dose discrepancy. In addition, a significantly positive correlation was observed between the predicted warfarin dose and the actual prescribed dose by Pearson correlation analysis (Fig. 3) .
Discussion and conclusion
In this study, we identified a group of mutations that were significantly associated with extreme warfarin dose; 10 SNPs passed the validation steps with a proper sample size. The new established pharmacogenetic algorithm included four newly identified warfarin dose-associated mutations that accounted for 56.2% of warfarin dose difference.
Use of the two-stage extreme phenotype approach allowed us to find casual mutations in a small sample size group, as much of the overall distribution of the phenotype was neglected [25] . However, extreme phenotype sampling also has limitations. Notably, the results might not be generalizable to the underlying population and might be sensitive to outliers, sampling bias, and the assumption of normality for the underlying traits. As the characteristics were grossly consistent between the two compared cohorts, the results of stage I were also hardly revalidated in the normal population (stage II). Second, if a complex trait is influenced by multiple gene loci, extreme phenotype sampling can reduce the power to detect loci with small effects. Third, the power of an CI, confidence interval; OR, odds ratio; SNP, single-nucleotide polymorphism. The G1 interval contained two SNPs (SNP96833210 and SNP968334982) of CYP2C8; patients with one or more mutant alleles of these two SNPs were defined as G1 mutant carriers, and patients with wild-type alleles of these two SNPs were defined as G1 wild-type carriers. The G2 interval contained five SNPs (rs61239537, rs12920772, rs72800847, rs12447930, and rs4889609) of STX1B; patients with one or more mutant alleles of these five SNPs defined as G2 mutant carriers, and patients with wild-type alleles of these five SNPs were defined as G2 wild-type carriers. extreme phenotype design can also be affected if variants in the two extremes have different directions of effect. In this study, extreme warfarin dose-associated mutations were not only different between the paired extreme dose groups, but also appeared to be not consistent among different VKORC1-1639 and CYP2C9*3 genotype groups. Hence, the statistical power of stage I may be difficult to calculate. The design of our study was similar to that of a previously published pharmacogenomics study of warfarin, which also used an extreme phenotype design to identify novel warfarin dose-associated mutations in African Americans [26] . However, these two studies had a number of different characteristics. First, the previous study was conducted with a small sample size (N = 360), and extreme sample selection in the discovery cohort was based on a high cutoff (~15%). Second, the effects of VKORC1-1639G>A and CYP2C9*3 polymorphisms were not taken into consideration before the sampling in their study. Third, only patients undergoing HVR surgery were enrolled in this study, and this strategy can reduce the sample selection bias. However, the whole exon capture and sequencing method was used in the study of Daneshjou et al. This sequencing method might be more effective than the target genes resequencing strategy to identify novel warfarin dose-associated genes.
After validation, the final established pharmacogenetic algorithm included seven mutations; the influences of VKORC1-1639G>A, CYP2C9*3 and CYP4F2 rs2108622 polymorphisms on warfarin dose were in accordance with the published data [27, 28] . The relationship between the other four mutations and warfarin dose have rarely been studied. The rs10517 polymorphism located in the 3 0 -UTR of NQO1 encodes a cytosolic enzyme that catalyzes the two-electron reduction of various quinones, including vitamin K. Data from a recent Korean population showed that the rs10517 polymorphism was responsible for a modest part of warfarin dose variability in HVR patients [29] . The results of both studies showed that patients with the rs10517 mutant allele need a higher warfarin dose than wild-type allele carriers.
STX1B encodes a synaptic protein, and is located 90 kb downstream of VKORC1. There is evidence that the STX1B polymorphism is associated with VKORC1 mRNA expression [20] . Findings regarding STX1B rs4889609 polymorphisms and warfarin dose vary between different ethnic groups. Data of the study of Hamadeh et al. showed that the rs4889609 polymorphism was independently associated with warfarin dose in European Americans [30] , whereas the results of Zhang et al.
showed that the STX1B rs4889606 polymorphism was significantly associated with warfarin dose by univariate analysis, but that this association was disappeared after performance of multiple regression analysis [17] .
The two SNPs (rs4889609 and rs72800847) of STX1B were in complete LD (r 2 = 1), and both were in close LD with VKORC1-1639G>A (r 2 = 0.609) in our study. Interestingly, the rs4889609 and rs72800847 mutations were independently and significantly associated with WSD in this study. Patients with the VKORC1-1639GA or VKORC1-1639AA genotype needed higher warfarin doses when they also had the rs4889609 or rs72800847 mutated genotype than VKORC1-1639GG genotype carriers (as shown in Table S5 ).
Previous studies have usually attributed the relationship between STX1B gene polymorphisms and WSD to the LD with VKORC1-1639G>A. After comparing the allele frequencies of VKORC1-1639G>A and STX1B rs4889609 and rs72800847 mutations in different populations, as shown in Table S8 , we found that the allele frequencies of these three mutations showed tremendous differences among various populations (referenced from the 1000 Genomes Project Phase 3 allele frequencies). The frequencies of rs4889609 and rs72800847 were similar in most populations, but showed large differences in Africans (1% versus 62%). Tremendous discrepancies in rs4889609 and rs72800847 frequencies were found between South Asians and East Asians; the South Asians had much higher frequencies of mutations than the East Asians (75% versus 9% for rs4889609; 74% versus 9% for rs72800847). There were also large frequency differences between VKORC1-1639G>A and rs4889609; rs72800847 also showed a large difference. Hence, we consider that more research should be conducted to determine the relationship between STX1B polymorphism and warfarin dose.
Our study first identified an intron mutation (rs2304429) of DNMT3A that significantly contributed to warfarin dose difference. DNA methyltransferases (DNMTs) catalyze DNA methylation at the 5-position of cytosine, which is the predominant epigenetic modification in mammals. Abnormal DNMT expression levels are usually associated with cancers, and DNMT3A mutations have been widely shown to be related to the prognosis of human acute myeloid leukemia [31, 32] . The relationship between DNMT3A polymorphism and warfarin dose was the first to be identified, implying that epigenetic alterations may also act as effective predictors for individualized warfarin treatment.
The association between the rs3826041 polymorphism, located upstream of CYP1A1, and warfarin dose discrepancy was also shown for the first time in this study. CYP1A1 encodes an important drug-metabolizing enzyme, which participates in the metabolism of R-warfarin. Although R-warfarin is less effective than S-warfarin, the rs3826041 polymorphism may affect the warfarin dose by influencing the expression of CYP1A1 and subsequently affecting the metabolism of R-warfarin.
The main challenges in the clinical use of warfarin are ascribed to its interindividual variability, narrow therapeutic index, and severe adverse effects. Also, patients who need extreme warfarin doses usually require a longer time to reach a therapeutic dose and have a higher risk of adverse effects. Previously established warfarin pharmacogenetics model cannot successfully provide an appropriate dose for patients who need extreme warfarin doses [9] . By using this two-stage extreme phenotype design, we successfully identified extreme dose-associated mutations for HVR patients. However, extreme dose-related genes and polymorphisms varied among different VKORC1-1639 and CYP2C9*3 genotype groups (as shown in Fig. S2A-C) . Even though we finally identified four mutations that are significantly associated with warfarin dose, we cannot provide a warfarin therapeutic approach for patients who need extreme doses in clinical practice.
The study has several limitations. First, the primary goal of our study was to resequence the functional areas of targeted genes. Notwithstanding the fact that deep resequencing has unparalleled resolution, a limitation of the targeted area resequencing method is that not every position in each gene can be effectively covered, meaning that true associated mutations can be missed. Second, only WSD was considered as a clinical outcome in our research, and the relationships between gene polymorphisms and other important endpoints, such as bleeding or embolism, were not investigated in our study. Third, SNPs that passed the validation of stage II were not further verified in the stage I population. Table S1 . Characteristics of extreme dose patients with (A) AA&*1*1, (B) GA&*1*1 or GG&*1*1 and (C) AA&*1*3 or AA&*3*3 genotypes. Table S2 . Concordance of the sequence-derived genotype calls with genotypes from MassArray genotyping for 18 SNPs. Table S3 . List of variations associated with extreme warfarin dose. Table S4 . Extreme warfarin dose-associated low allele frequency mutations. Table S5 . Frequency of G2 gene locus in different genotype groups. Table S6 . Basic information of validated mutations. Table S7 . Primers of the validated mutations. Table S8 . Frequencies of rs9923231, rs72800847 and rs4889609 in different populations. Fig. S1 . Warfarin dose-associated candidate genes or areas. Fig. S2 . P-values of each SNP associated with warfarin dose in different genotype groups. The horizontal axis shows SNP location, and the vertical axis is À log10(Pvalue) for each SNP tested by correlation analysis. Significantly associated SNPs with P-values beyond 0.05 are denoted by a red horizontal line.
